| Phase 3 |
| NCT07524452 |
Becotatug Vedotin (MRG003) in Combination With PD-1 Inhibitor Versus PD-1 Inhibitor for… |
Locally Advanced Head and Neck Squamous Cell Carcinoma |
Recruiting |
2026-04-13 |
| NCT07481799 |
Efficacy and Safety of SBRT Combined With Becotatug Vedotin (MRG003) in EGFR-Positive… |
Oligo-metastatic Cancer |
Recruiting |
2026-04-02 |
| NCT07328841 |
Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally… |
Nasopharyngeal Carcinoma (NPC) |
Recruiting |
2026-01-09 |
| NCT07328854 |
40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II… |
Nasopharyngeal Carcinoma |
Recruiting |
2026-01-09 |
| NCT07188584 |
Phase III Non-Inferiority Trial: Reduced-Target vs. Full-Target IMRT After Chemo in… |
Nasopharyngeal Carcinoma (NPC) |
Recruiting |
2025-12-09 |
| Phase 2 |
| NCT07581821 |
Sintilimab Combined With Anlotinib and Taxane-Based Chemotherap for Recurrent/Metastatic… |
Recurrent or Metastatic Nasopharyngeal Carcinoma |
Recruiting |
2026-05-12 |
| NCT07070479 |
Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma… |
Recurrent or Metastatic Nasopharyngeal Carcinoma |
Recruiting |
2025-09-18 |
| NCT06472713 |
Clinical Study of Mitoxantrone Hydrochloride Liposome Combined with PD-1 Blockade in… |
Recurrent or Metastatic Nasopharyngeal Carcinoma |
Recruiting |
2025-01-13 |
| Not applicable |
| NCT06870435 |
Comparison and Strategy Optimization of Plasma EBV DNA and P85-Ab with VCA/EBNA1-IgA for… |
Nasopharyngeal Carcinoma (NPC) |
Recruiting |
2025-03-11 |
| NCT06688760 |
Surgery Alone Verus Sugery Combined with Dose-reduced Radiotherapy for Newly Diagnosed… |
Nasopharyngeal Carcinoma |
Recruiting |
2024-11-14 |
| NCT06529562 |
Surgery Plus Reduced Target Chemoradiotherapy vs Surgery Plus Reduced Dose… |
Nasopharyngeal Carcinoma |
Recruiting |
2024-07-31 |
| Not specified |
| NCT06787456 |
"Xijiang Project" Screening Cohort for NPC |
Nasopharyngeal Carcinoma (NPC) |
Recruiting |
2026-09-01 |